REMARKS

1. Group Restriction Requirement

As issued on August 2, 2006, the pending Office Action requires that the Applicant elect claims from either Group I (Claims 1-8) or Group II (Claims 10-14) for further prosecution in this application. Pending Claims 9 and 15-20 were not addressed by the Examiner in the issued Office Action. In a helpful discussion with Examiner Gucker on August 28, 2006, the Examiner stated that the non-address claim were merely overlooked, and agreed that Claims 9 and 15-20 should be joined with the other Group II claims designated in the restriction requirement issued on August 2, 2006. Applicant agreed with Examiner's recommendation that no new formal restriction requirement would be necessary. As a result, Group II now comprises Claims 9-20.

Applicant elects the Group II claims for further examination in this application. Applicant also has added new claim 21 drawn to a process of using the products of claims 15-20, respectively. Support for new claim 21 may be found in original claims 1-8. Applicant submits that new claim 21, which is a linking claim, should be considered with the Group II product claims. Examination of claim 21 does not impose an undue burden on the Examiner. Applicant has cancelled claims 1-8.

This paper is filed within the one-month time for reply. It is believed that no other fees are due for this application under 37 C.F.R. §§ 1.16-1.22. If any fee is due for this application, however, the Commissioner is authorized to deduct the fee from Deposit Account No. 08-3038/**11362.0016.DVUS01**.

Respectfully submitted,

Patricia A. Kammerer
Reg. No. 29,775
Attorney for Assignee
INNOGENETICS N.V.

Customer No. 23369
HOWREY LLP
1111 Louisiana, 25th Floor
Houston, Texas 77002
(713) 787-1512 (direct)

Date: September 5, 2006